Update on the pathophysiology and management of gastro-oesophageal reflux disease: The role of prokinetic therapy

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 6, 1996, Pages 603-611

  Tytgat, Guido N J ^a   Janssens, Jozef ^b   Reynolds, James C ^c   Wienbeck, Martin ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Zentralklinikum ^*  (Germany)

Author keywords

Cisapride; Gastro oesophageal reflux disease; Prokinetic agents

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

BARRETT ESOPHAGUS; CLINICAL TRIAL; ESOPHAGUS MOTILITY; ESOPHAGUS MUCOSA; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH PARESIS; SYMPTOMATOLOGY;

EID: 0029987570     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199606000-00020     Document Type: Review

References (78)

1. Spechler SJ: Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992, 15(Suppl 1):24-29.
2. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC: Esophageal peristaltic dysfunction in peptic oesophagitis. Gastroenterotogy 1986, 91:897-904.
3. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK, et al.: Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982, 307:1547-1552.
4. Dent J, Holloway RH, Toouli J, Dodds WJ: Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastro-oesophageal reflux. Gut 1988, 28:1020-1028.
5. Genta RM, Huberman RM, Graham DY: The gastric cardia in Helicobacter pylori infection. Human Pathol 1994, 25:915-919.
6. Mittal RK, Fisher M, MacCallum RW, Rochester DF, Dent J, Sluss J: Human lower oesophageal sphincter pressure response to increased intraabdominal pressure. Am J Physiol 1990, 21:G624-G630.
7. Sloan S, Kahrilas PJ: Impairment of oesophageal emptying with hiatal hernia. Gastroenterology 1991, 100:596-605.
8. Stanciu C, Bennett JR: Oesophageal acid clearing: one factor in the production of reflux oesophagitis. Gut 1974, 15:852-857.
9. Johnson LF: 24-hour pH monitoring in the study of gastro-oesophageal reflux. J Clin Gastroenterol 1980, 2:377-399.
10. Schleisinger PK, Donahue PE, Schmid B, Layden TJ: Limitations of 24-hour intraoesophageal pH monitoring in the hospital setting. Gastroenterology 1985, 89:797-804.
11. Schoeman MN, de Tippett M, Akkermans LMA, Dent J, Holloway RH: Mechanisms of gastro-oesophageal reflux in ambulant healthy subjects. Gastroenterology 1995, 108:83-91.
12. Mittal RK, Lange RC, MacCallum RW: Identification and mechanism of delayed oesophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987, 92:130-135.
13. Helm JF, Dodds WJ, Pelc R, Palmer DN, Hogan WJ, Teeter BC: Effect of oesophageal emptying and saliva on clearance of acid from the oesophagus. N Engl J Med 1984, 310:284-286.
14. Orlando RC: Pathophysiology of gastrooesophageal reflux. Oesophageal epithelial resistance. In The Oesophagus. Edited by Castell DO. New York: Little Brown; 1992:463-478.
15. Safaie-Shirazi S, DenBesten L, Zike WL: Effect of bile salts on the ionic permeability of the oesophageal mucosa and their role in the production of oesophagitis. Gastroenterology 1975, 68:728-733.
16. Jankowski J, Murphy S, Coghill G, Grant A, Wormsley KG, Sanders DS, et al.: Epidermal growth factor receptors in the oesophagus. Gut 1992, 33:439-443.
17. + injury in rabbit oesophageal epithelium. Am J Physiol 1984, 246:G718-G724.
18. Cunningham KM, Horowitz M, Riddell PS, Maddern GI, Myers JC, Holloway RH, et al.: Relations among autonomic nerve dysfunction oesophageal motility and gastric emptying in gastro-oesophageal reflux disesase. Gut 1991, 32:1436-1440.
19. Sifrim D, Vantrappen G, Janssens J: Permissive role of the oesophageal body during transient lower oesophageal sphincter relaxations [abstract]. Neurogastroenterol Mot 1994, 6:171.
20. Sifrim D: Inhibition in the human esophageal body. Its role in normal and disordered motility [thesis]. Leuven, 1994.
21. Janssens J, Sifrim D, Lerut A: Esophageal motility disorders: a pathophysiological concept [abstract]. Gastroenterology 1995, 108:A621.
22. Howard PJ, Heading RC: Epidemiology of gastrooesophageal reflux disease. World J Surg 1992, 16:288-293.
23. Castell DO. In Gastrooesophageal Reflux Disease: Pathogenesis, Diagnosis, Therapy. Edited by Castell DO, Wu WC, Ott DJ. Mount Kisco, New York: Futura, 1985.
24. Sontag SJ: Rolling review: gastrooesophageal reflux disease. Aliment Pharmacol Ther 1993, 7:293-312.
25. Urschel HC, Paulson DL: Gastro-oesophageal reflux and hiatal hernia. J Thorac Cardiovasc Surg 1967, 53:21-32.
26. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, et al.: Barrett's oesophagus. A prevalent, occult complication of gastro-oesophageal reflux disease. Gastroenterology 1987, 92:118-124.
27. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994, 344:1533-1536.
28. Johnson DA, Winters C, Spurling TJ, Chobanian SJJ: Oesophageal acid sensitivity in Barrett's oesophagus. J Clin Gastroenterol 1987, 9:23-27.
29. Gaynor EB: Otolaryngologic manifestations of gastroesophageal reflux. Am J Gastroenterol 1991, 86:801-808.
30. Pope CE. Acid-reflux disorders. N Engl J Med 1994, 331:656-660.
31. Koufman JA: The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101:1-78.
32. 2-blockers, antacids and prokinetic drugs. Scand J Gastroenterol 1989, 24(Suppl. 156):25-36.
33. Maton P: Omeprazole. N Engl Med 1991, 324:965-975.
34. Cloud, ML, Offen WW and the Nizatidine Castroesophageal Reflux Disease Study Group: Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Dig Dis Sci 1992, 37:865-874.
35. Tytgat GNJ, Nicolai JJ, Reman FC: Efficacy of different doses of cimetidine in the treatment of reflux oesophagitis. Gastroenterology 1990, 99:629-634.
36. Palmer RH, Frank WO, Rockhold FW, Wetherington JD, Young MD: Cimetidine 800mg twice daily for healing erosions and ulcers in gastro-oesophageal reflux disease. J Clin Gastroenterol 1990, 12(Suppl. 2):29S-34S.
37. Euler AR, Murdock RH, Wilson TH, Silver MT, Parker SE, Powers L: Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 1993, 88:520-524.
38. Wesdorp ICE, Dekker W, Festen HPM: Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux oesophagitis. Dig Dis Sci 1993, 38:2287-2293.
39. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992, 51(Suppl. 1):59-67.
40. Hunt RH, Cederberg C, Dent I, Halter F, Howden C, Solly Marks IN, et al.: Optimising acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40(Suppl. 2): 24S-49S.
41. Barradell LB, McTavish D: Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis. Pharmacoeconomics 1993, 3:482-510.
42. + ATPase inhibitor. Am J Gastroenterol 1993, 88:1212-17.
43. Dent J: Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1994, 29(Suppl. 201):55-61.
44. Collen MJ, Johnson DA, Sheridan MJ: Basal acid output and gastric acid hypersecretion in gastro-oesophageal reflux disease. Correlation with ranitidine therapy. Dig Dis Sci 1994, 39:410-417.
45. MacCallum RW: Cisapride: a new class of prokinetic agent. Am J Gastroenterol 1991, 86:135-49.
46. Vaz Safatle Ribeiro A, Reynolds IC: Cisapride: mechanisms of action and potential applications. Today's Ther Trends 1994, 12:1-23.
47. Collins BJ, Spence RAJ, Ferguson R: Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with gastro-oesophageal reflux disease. Hepatogastroenterology 1987, 34:113-116.
48. Creytens G: Activity profile of cisapride. Progr Med 1987, 43:35-41.
49. Nicolaidis CL, Kehagioglou K, Mantzaris G, Papabapou-Marinou A, Saklardis J, Georgiotos D, et al.: Therapeutic effect of two doses of cisapride in controlling chronic reflux symptoms in oesophagitis patients. Curr Ther Res 1987, 42:1059-1065.
50. Baldi F, Bianchi-Porro G, Dobrilla G, Iascone C, Lobello R, Marzio L, et al.: Cisapride versus placebo in reflux oesophagitis. A multi-centre double-blind trial. J Clin Gastroenterol 1988, 10:614-618.
51. Hüttemann W: In Progress in the Treatment of Gastrointestinal Motility Disorders: the Role of Cisapride. Edited by Johnson and Lux. Amsterdam: Excerpta Medica, 1988:56-61.
52. Lepoutre L: In: Progress in the Treatment of Gastrointestinal Motility Disorders: the Role of Cisapride. Edited by Johnson and Lux. Amsterdam: Excerpta Medica; 1988:63-65.
53. Martin-Abreu L, Castel Branco da Silveira JJ, Hadad MT, Feldman R, Mat MR, Leitao OR, et al.: Cisapride controls chronic gastro-oesophageal reflux symptoms in patients with oesophagitis. Today's Therapeutic Trends 1988, 6:1-11.
54. Van Outryve M, Vanderlinden I, Dedullen G, Rutgeerts L: Dose-response study with cisapride in gastrooesophageal reflux disease. Curr Ther Res 1988, 43:408-415.
55. Evreux M, Fournet J, Galmiche JP, Soule J, Vitaux J, Zeitoun P, et al.: Endoscopic and clinical evaluation of cisapride and cimetidine in reflux oesophagitis [abstract]. Gastroenterology 1988, 94:A120.
56. Janisch H, Hüttemann W, Bouzo MH: Cisapride versus ranitidine in the treatment of reflux oesophagitis. Hepatogastroenterology 1988; 35:125-127.
57. Geldof H, Hazalhoff B, Otten MH: Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993, 7:409-415.
58. Maleev A, Mendizova A, Popov P, Vlahov V, Dimitrov B, Mihova A, et al.: Cisapride and cimetidine in the treatment of erosive oesophagitis. Hepatogastroenterology 1990, 37:403-407.
59. Inauen W, Emde C, Weber B, Armstrong D, Bettschen HU, Huber T, et al.: Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24-hour ambulatory combined pH and manometry study. Gut 1993, 34:1025-1031.
60. Ben Rejeb M, Bouche O, Zeitoun P: Study of 47 consecutive cases with peptic oesophageal stricture compared with 3880 cases of reflux oesophagitis. Dig Dis Sci 1992, 37:733-736.
61. Basilisco G, Barbera R, Molgora M, Vanoli M, Bianchi Porro G: Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis. Gut 1993, 34:1487-1491.
62. Galmiche JP, Des Varannes B: Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol 1994, 29(Suppl. 201):62-68.
63. Reynolds JC: Individualised acute treatment strategies for gastro-oesophageal reflux disease. Scand J Gastroenterol 1995, 30(Suppl. 213) :17-24.
64. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, et al.: Long term sequelae of Helicobacter pylori gastritis. Lancet 1995, 345:1525-1528.
65. Boulant J, Fioramonti J, Dapoigny M, Bommelaer G, Bueno L: Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distention in dogs. Gastroenterology 1994, 107:1059-1066.
66. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J: Transient lower oesophageal sphincter relaxations. Gastroenterology 1995, 109:601-610.
67. Johnson NJ, Boyd EJS, Mills JG, Wood JR: Acute treatment of reflux oesophagitis: a multicentre trial to compare 150mg ranitidine bd with 300 mg ranitidine qds. Aliment Pharmacol Ther 1989, 3:259-266.
68. Roufail W, Belsito A, Barish C, Rubin A and the Glaxo Erosive Oesophagitis Study Group: Ranitidine for reflux oesophagitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 1992, 6:597-607.
69. Simon TJ, Berenson MM, Berlin RG: Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. Aliment Pharmacol Ther 1994, 8:71-79.
70. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al.: Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 1988, 95:903-912.
71. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA: Three year follow-up of patients with gastro-oesophageal reflux disease. Gut 1992, 33:1016-1019.
72. Kuster E, Ros E, Toledo-Pimentel V, Pujol A, Bordas JM, Grande L, et al.: Predictive factors of the long-term outcome in gastro-oesophageal reflux disease: six year follow-up of 107 patients. Gut 1994, 35:8-14.
73. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al.: Long-term treatment with omeprazole for refractory reflux oesophagitis: efficacy and safety. Ann Intern Med 1994, 121:161-167.
74. Tytgat GNJ, Anker-Hansen OJ, Carling L, De Groot GH, Geldof J, Glise H, et al.: Effect of cisapride on relapse of reflux oesophagitis healed with an antisecretory drug. Scand J Gastroenterol 1992, 27:175-183.
75. Toussaint J, Gossuin A, Deruyttere M, Huble F, Devis G. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991, 32:1280-1285.
76. Blum AL, Adami B, Bouzo MH, Bransdtatter C, Fumagalli I, Galmiche JP, et al.: Effect of cisapride on relapse of oesophagitis: a multinational placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993, 38:551-560.
77. Kimmig JM. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Aliment Pharmacol Ther 1995, 9:281-286.
78. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al.: A comparison of five maintenance therapies for reflux oesophagitis. N Engl J Med 1995, 333:1106-1110.